Inventiva Pharma

Inventiva Pharma Overview

  • Status
  • Public
  • Employees
  • 88
Employees
  • Stock Symbol
  • IVA
Stock Symbol
  • Share Price
  • $15.31
  • (As of Thursday Closing)

Inventiva Pharma General Information

Description

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis and rare diseases. All the company's operations are located in France. The majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
PAR
Primary Office
  • 50 rue de Dijon
  • 21121 Daix
  • France
+33 03 00 00 00 00

Inventiva Pharma Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Inventiva Pharma Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$15.31 $16.10 $1.71 - $16.98 $468M 30.6M 150K -$1.43

Inventiva Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2019 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 68,108 68,108 55,439 24,027
Revenue 7,834 7,834 3,773 5,410
EBITDA (32,369) (32,369) (38,389) (23,919)
Net Income (33,827) (33,827) (39,670) (21,521)
Total Assets 63,805 63,805 91,297 89,218
Total Debt 128 128 257 578
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Inventiva Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial

Inventiva Pharma Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Zynerba Pharmaceuticals Formerly VC-backed Devon, PA 00 00000 00000000 00000
00000 Formerly VC-backed Paris, France 00 00000 000000000 00000
000 00000000(00000 Corporate Backed or Acquired Cambridge, MA 000 000.00 00000000 000.00
0000000000 Corporate Backed or Acquired Baton Rouge, LA 000000000000
0000 000000000000 Formerly VC-backed Flemington, NJ 0 000.00 00000000 00

Inventiva Pharma Executive Team (4)

Name Title Board Seat Contact Info
Frédéric Cren Co-Founder, Chief Executive Officer and Chairman
Jean Volatier Chief Financial Officer
Pierre Broqua Ph.D Co-Founder, Board Member, Deputy General Manager and Chief Scientific Officer
Jean-Louis Abitbol MD Chief Medical Officer and Head of Development

Inventiva Pharma Board Members (1)

Name Representing Role Since
00é0é000 0000 Inventiva Pharma Co-Founder, Chief Executive Officer and Chairman 000 0000

Inventiva Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Inventiva Pharma‘s full profile, request access.

Request a free trial

Ready to get started?

Request a free trial